Seer, Inc. (NASDAQ:SEER)
| Market Cap | $75.91M-31.0% |
| Revenue (ttm) | $13.86M-13.3% |
| Net Income | -$63.47M+20.0% |
| EPS | -$1.15+14.2% |
| Shares Out | 55.81M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 130,275 |
| Open | $1.38 |
| Previous Close | $1.39 |
| Day's Range | $1.33 - $1.38 |
| 52-Week Range | $1.33 - $2.38 |
| Beta | 1.45 |
| Analysts | Hold |
| Price Target | $4.00(+194.12%) |
| Earnings Date | Mar 4, 2027 |
About SEER
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 4, 2027Earnings report
$SEER stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in SEER holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SEER's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SEER Estimated quarterly lobbying spending
Source: U.S. Senate LDA
SEER Revenue by Segment
| Stock-based compensation | $1.22M | 68.91% |
| Other | $550.00K | 31.09% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New SEER patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SEER from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SEER
| VTIVanguard Morningstar Total Stock Market ETF | $1.62M |
| VXFVanguard Extended Market ETF | $838.42K |
| IWCiShares Micro-Cap ETF | $176.31K |
| BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | $90.00K |
| AVSCAvantis U.S. Small Cap Equity ETF | $85.22K |
| DFMCU.S. Micro Cap Portfolio ETF | $52.39K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from SEER’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 2026 revenue growth with positive guidance update supports bullish tone, though coverage focuses on reporting facts rather than strong analyst enthusiasm.
